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Objectives: Once a core outcome set (COS) has been defined, it is important to achieve 
consensus on how these outcomes should be measured. The aim of this systematic review is 
to gain insight into the methods used to select outcome measurement instruments and 
determine whether methods have improved following the COSMIN/COMET guideline 
publication. 
Study Design and Setting: Eligible articles, which were identified from the annual COMET 
systematic review, concerned any COS development studies that provided a recommendation 
on how to measure the outcomes included in the COS. Data was extracted on the methods 
used to select outcome measurement instruments in accordance with the COSMIN/COMET 
guideline. 
Results: Of the 118 studies included in the review, 48% used more than one source of 
information when finding outcome measurement instruments and 74% performed some form 
of quality assessment of the measurement instruments. Twenty-three studies recommended 
one single instrument for each core outcome included in the COS. Clinical experts and public 
representatives were involved in selecting instruments in 62% and 28% of studies, 
respectively.  
Conclusion: Methods used to select outcome measurement instruments have improved since 
the publication of the COSMIN/COMET guideline. Going forward COS developers should 
ensure that recommended outcome measurement instruments have sufficient content validity. 
In addition, COS developers should recommend one instrument for each core outcome to 
contribute to the overarching goal of uniformity in outcome reporting. 
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What is new? 1 
 2 
Key findings 3 
• Methods used to select core outcome measurement instruments vary across studies, 4 
with many studies not meeting the recommended standards. 5 
• Methods used to select outcome measurement instruments have improved since the 6 
publication of the COSMIN/COMET guideline. 7 
 8 
What this adds to what is known? 9 
• This is the first study to assess how the outcome measurement instruments 10 
recommended in existing core outcome sets have been sel cted and whether good 11 
practices are being followed. 12 
 13 
What is the implication, what should change now? 14 
• Core outcome set developers need to make better use of th  guidance available when 15 
agreeing on how to measure the outcomes included in core outcome sets.  16 
• Developers need to ensure that outcome measurement instruments are of sufficient 17 








^When using the term ‘outcome measurement instruments’ we are referring to any instruments, 
definitions, tools, procedures, etc., that are used to measure an outcome.  
6
1. Introduction 26 
 27 
There is lack of consensus with regard to the selection of outcomes and outcome 28 
measurement instruments for clinical trials, which causes inconsistencies in the outcomes 29 
reported and difficulties in comparing these outcomes in systematic reviews and meta-30 
analyses.[1] In addition, there is great variability in the quality of outcome measurement 31 
instruments used, and it is not always clear if the best instrument is being used for a given 32 
outcome. To overcome these issues, standardisation of the selection of outcomes and 33 
outcome measurement instruments is needed. 34 
 35 
The Core Outcome Measures in Effectiveness Trials (COMET) Initiative (www.comet-36 
initiative.org), launched in January 2010, aims to facilitate the development and application 37 
of agreed standardized sets of outcomes, also known as ‘Core Outcome Sets’ (COS). A COS 38 
is an agreed minimum set of outcomes that should be measured and reported in all clinical 39 
trials of a specific disease or trial population (i.e. what to measure).[1] Once the COS has 40 
been defined, it is then important to achieve consensus on how these outcomes should be 41 
measured (i.e. how to measure).  42 
 43 
The COSMIN initiative (COnsensus-based Standards for the selection of health Measurement 44 
Instruments, http://www.cosmin.nl/) aims to improve th  selection of outcome measurement 45 
instruments.^ In 2016, COSMIN and COMET published a consensus-based guideline on how 46 
to select outcome measurement instruments for outcomes included in a COS.[2] Among a 47 
large group of international stakeholders from 14 different countries, including clinicians, 48 
clinimetricians/psychometricians, epidemiologists, journal editors, physicians, researchers, 49 
and statisticians, consensus was obtained on methods for selecting outcome measurement 50 
 
instruments for outcomes included in a COS. COS developers are guided through the process 51 
of instrument selection in four consecutive steps: Step 1, conceptual considerations; Step 2, 52 
finding existing outcome measurement instruments; Step 3, quality assessment of outcome 53 
measurement instruments; Step 4, recommendations on the selection of outcome 54 
measurement instruments. It is unknown, however, how t e outcome measurement 55 
instruments recommended in existing COS have actually been selected by COS developers 56 
and whether good practices for COS development, as described in the COSMIN/COMET 57 
guideline are being followed.  58 
 59 
The aim of this systematic review is to: (1) gain insight into the methods used by COS 60 
developers for selecting core outcome measurement instruments; and (2) determine whether 61 
the methods have improved following the 2016 publication of the COSMIN/COMET 62 
guideline. It is hypothesised that the quality of the methods used to select the core outcome 63 
measurement instruments varies considerably, and it is therefore anticipated that there will be 64 
considerable room for improvement in COS development with regard to instrument selection.  65 
However, there are expected to be improvements in the methods used in studies that have 66 
been published from 2017 onwards.  67 
 68 
2. Methods 69 
 70 
2.1. Eligibility criteria 71 
Eligible articles concern COS development studies that provide recommendations on what 72 
and how to measure, either done together in one study or done in two separate stages (i.e. two 73 
or more studies). We included all COS studies, ident fi d from the original COMET 74 
systematic review and annual updates,[3-8] that provided a recommendation on the 75 
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instruments to measure the outcomes included in the COS. COS development studies that 76 
only provide a recommendation on what to measure, but do not consider how to measure, and 77 
studies that discuss how to measure the outcomes but do not give a recommendation were 78 
excluded. 79 
 80 
2.2. Literature search 81 
The search strategy for identifying eligible COS development studies has been described 82 
elsewhere in detail.[3-8] In brief, a comprehensive search strategy to identify studies that 83 
aimed to define COS in any disease area was first developed in 2013[3] (see Appendix A for 84 
full search strategy). Database searches were repeated in 2015,[4] 2016,[5], 2017[6], 2018[7] 85 
and 2019.[8] 86 
 87 
2.3. Data extraction 88 
Four sets of reviewers (CP-SG, SG-MSK, MSK-CP, SG-KMS) independently extracted data 89 
on descriptive information for each identified COS, including the target population, disease 90 
area, and the (number of) outcomes. Data has been extract d in accordance with the 91 
COSMIN/COMET guideline (see flowchart in Appendix B). Methods used to select 92 
instruments for the COS have been extracted, including the approach taken to identify 93 
existing instruments, the evaluation of the quality and feasibility of instruments, the number 94 
of instruments recommended for use, arguments used for selecting instruments other than 95 
quality criteria (measurement properties), recommendations for additional research on 96 
instruments, and whether any guidance for instrument s lection, including the 97 
COSMIN/COMET guideline, was followed (see Appendix C). To ensure consistency in data 98 
extraction, the data extraction form was pilot tested for a set of five studies and the extracted 99 
data was compared before extracting data for the remaining studies. Discrepancies in data 100 
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extraction between pairs of reviewers were sought to be resolved by discussion with the third 101 
reviewer and consensus was reached.  102 
 103 
To improve the quality of our data, first authors of the included studies were contacted in 104 
person by email to verify the data extracted from their studies and they were asked to provide 105 
additional information that might be missing. In case the email could not be delivered, the 106 
last author of that particular study was contacted by email. References of the included papers 107 
were also checked to identify any other relevant articles on instrument selection for COS. 108 
 109 
3. Results 110 
A total of 163 articles describing 118 COS development studies were included in the review. 111 
A flow diagram of the article and abstract selection process is provided in Figure 1, guided by 112 
PRISMA.[9]   113 
 114 
Details on COS development studies (e.g. target population, disease area) can be found in 115 
Appendix D. In summary, COS were developed in a variety of geographical locations, 116 
including Asia, Canada, Europe, New Zealand, South Africa, South America, and USA. All 117 
COS were developed in the English language. The number of core outcomes included in the 118 
COS varied between two[10, 11] and 26.[12] Following the COMET classifications[13] COS 119 
were developed in 24 different disease areas, mostly neurology (n=19 studies), rheumatology 120 
(n=14), heart & circulation (n=13), and orthopaedics & trauma (n=11). In 36 studies, the 121 
COS were developed for adults; in 17 studies for children and in 20 studies for both adults 122 
and children. In 45 studies (38%), the age group for which the COS was developed was not 123 
specified. Of the 118 studies, 23 studies reported on core outcomes for different subgroups of 124 
patients, such as age groups;[14-16] acute or chronic c ditions;[17] disease severity;[18, 19] 125 
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type of study, for example prevention trials vs intervention trials[20, 21] or phase I-II vs 126 
phase III clinical trials;[15] for acute vs long-term treatment[22] or acute treatment vs 127 
prophylaxis;[23-25] for different diseases/conditions;[16, 26-32] or for different settings.[33, 128 
34]  129 
 130 
3.1. Methods used in the selection of instruments for COS 131 
With regard to COS development, 87/118 COS studies us d a single process to identify the 132 
core outcomes as well the instruments recommended to measure these outcomes; whereas 31 133 
studies used a two stage process that involved first agreeing on 'what to measure' (select core 134 
outcomes) before moving onto the 'how to measure' (recommend instruments). 135 
 136 
3.1.1. Finding existing outcome measurement instruments 137 
It is recommended that COS developers aim for finding all existing outcome measurement 138 
instruments. Multiple sources of information can be us d to find instruments: (1) performing 139 
a systematic review, including a search in MEDLINE (and EMBASE); (2) use existing 140 
review(s); (3) reference lists; (4) expert opinion; r (5) other sources of information, such as 141 
online databases, book (chapters) or conference proceedings.[2] Of the 118 included studies, 142 
21 studies (18%) used three or more sources of information when finding existing outcome 143 
measurement instruments and 36 studies (30%) used two sources of information. Sixty-one 144 
studies (52%) used only one source of information when finding existing outcome 145 
measurement instruments, with 39/61 studies accessing expert opinion only. Of the 118 146 
studies, 52 studies (44%) performed a systematic rev ew; 19 studies (16%) used an existing 147 
review; seven studies (6%) searched reference lists; 49 tudies (42%) accessed expert 148 
opinion; and 15 studies (13%) used other sources of inf rmation, mostly instruments used in 149 




3.1.2. Quality assessment of outcome measurement instruments 152 
COS developers should base their recommendations for outcome measurement instruments 153 
on (1) the quality of the existing outcome measurement instruments, i.e. their measurement 154 
properties (including an evaluation of the quality of the validation studies), and (2) the 155 
feasibility aspects of the outcome measurement instruments.[2]  156 
 157 
3.1.2.1. Measurement properties 158 
It is recommended that evidence on the measurement properties of outcome measurement 159 
instruments should be available in the target population. The quality of instruments is 160 
determined in studies on measurement properties, which s ould be of high methodological 161 
quality. Of the 118 studies, six studies[35-40] (5%) considered both the results of the 162 
measurement properties of the outcome measurement instruments and the quality of studies 163 
on these measurement properties. However, in three of these studies[35, 36, 38] it remains 164 
unclear whether a best evidence synthesis was performed. COS developers of 23/118 studies 165 
(20%) only considered the results of the measurement properties of the included outcome 166 
measurement instruments, but did not consider the quality of the studies on these 167 
measurement properties. In 58/118 studies (49%), COS developers referred to quality criteria 168 
of outcome measurement instruments, however there was no mention of any formal 169 
assessment of whether the instruments met these criteria. COS developers of 31/118 studies 170 
(26%) did not take the quality of the outcome measurement instruments into account when 171 
making their recommendations.   172 
 173 
3.1.2.2. Feasibility 174 
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Of the 118 studies, 74 studies (63%) have taken feasibility aspects into consideration in the 175 
selection of instruments for the COS, such as availbility of the instrument, cost of an 176 
instrument, ease of administration, and length of an instrument. In 44 studies (37%) there was 177 
no indication that feasibility was taken into consideration in the selection of instruments for 178 
the COS.  179 
 180 
3.1.3. Recommendations on the selection of outcome asurement instruments 181 
It is advised to recommend only one outcome measurement instrument for each core outcome 182 
per subdomain/subpopulation in the COS, as this will serve the ultimate goal of 183 
standardization of outcome reporting.[2] Of the 118 studies, only 11 studies (9%) 184 
recommended one single instrument for each core outcome included in the COS.[12, 38, 39, 185 
41-48] In seven of these 11 studies, one instrument was selected for each core outcome 186 
(range: 4-26) in the COS.[12, 38, 41, 43, 44, 47, 48] In three studies, one instrument was 187 
recommended for each core outcome or for each subpop lation (i.e. children and adolescents) 188 
(range of core outcomes: 4-10).[42, 45, 46] In one study, one instrument was recommended 189 
for each of the four core outcomes, with two alternative instruments recommended for two of 190 
the outcomes because they were free of charge.[39] In 12 of the 118 studies (10%), one 191 
single instrument was recommended for each core outcome other than those for which no 192 
outcome measurement instrument could be recommended (range of core outcomes with 193 
instrument recommended: 1-17).[21, 37, 49-58] Twelve of the 118 studies (10%) 194 
recommended one instrument for all included core outcomes except one (range included core 195 
outcomes: 3-15).[25, 35, 40, 59-67] Another seven studies (6%) recommended multiple 196 
instruments for all core outcomes included in the COS.[19, 36, 68-72] In 76/118 studies 197 
(64%) a combination of recommendations was used in the selection of instruments for each 198 
core outcome included in the COS (i.e. for some outcomes one instrument was 199 
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recommended, for some outcomes multiple instruments were recommended, either for the 200 
entire group or for different subgroups and for some outcomes no instrument was 201 
recommended).  202 
 203 
3.1.4. Consensus procedure used to reach agreement 204 
It is recommended that COS developers use a consensus procedure to get final agreement on 205 
the selected instruments included in the COS.[2] In 80/118 studies (68%) a consensus 206 
procedure was used. In 30/80 studies it was unclear and not specified how consensus was 207 
obtained. In 8/80 studies COS developers used a Delphi t chnique to reach consensus on the 208 
selection of core instruments.[12, 43, 48, 64, 73-76] Six of the 80 studies were guided by the 209 
OMERACT consensus and validation process, which involved participants voting and then 210 
breaking out into groups to review and discuss domains nd instruments.[39, 40, 63, 72, 77, 211 
78] In 36/80 studies COS developers conducted a consensus meeting, including various 212 
methods, to reach consensus on the core instruments. Con ensus methods used at the 213 
meetings included presentations, nominal group techniques, group discussions, consensus 214 
workshops, breakout sessions and voting. In 38/118 studies (32%), no consensus procedure 215 
was used to agree on the instruments included in the COS and recommendations were 216 
formulated by the COS developers.  217 
 218 
3.1.4. Stakeholders involved in the selection of outcome measurement instruments 219 
Of the 118 studies, the following stakeholders were involved in the selection of outcome 220 
measurement instruments: clinical experts (n=73), non-clinical researchers (n=39), patients 221 
and/or public representatives (n=33), regulatory authorities (n=20) and industry 222 
representatives (n=17). An additional 43 studies did not provide any details about the 223 
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stakeholders involved in selecting the outcome measur ment instruments. Table 1 displays 224 
the different stakeholder combinations across the 118 studies.  225 
 226 
Table 1. Number of studies involving each stakeholder group combination 227 
Stakeholder groups n (%) 
Clinical experts  19 (16) 
Clinical experts, public representatives and non-cli ical research experts 11 (9) 
Clinical experts and non-clinical research experts 8 (7) 
Clinical experts and public representatives 7 (6) 
Clinical experts, public representatives, non-clinial research experts and industry 
experts 
6 (5) 
Clinical experts, public representatives, non-clinial research experts, authorities and 
industry experts 
4 (3) 
Clinical experts, public representatives, non-clinial research experts and authorities 3 (3) 
Clinical experts, non-clinical research experts anduthorities 3 (3) 
Clinical experts, authorities and industry experts 3 (3) 
Clinical experts, public representatives and authorities 2 (2) 
Clinical experts and authorities 2 (2) 
Clinical experts and other 2 (2) 
Clinical experts, non-clinical research experts, authorities and industry experts 2 (2) 
Clinical experts and industry experts 1 (1) 
Non-clinical research experts, authorities and industry experts 1 (1) 
Non-clinical research experts 1 (1) 
No details provided 43 (36) 
 228 
3.1.5. Guidance on instrument selection 229 
In 35/118 studies (30%) published guidance for instrument selection was used. Most studies 230 
(n=13) used the OMERACT guidance,[79] whereas other studies used the Grading of 231 
Recommendations, Assessment, and Evaluation (GRADE) approach;[16, 80] IMMPACT 232 
recommendations;[81, 82] WHO-ICF framework;[83, 84]EULAR operating procedures;[85] 233 
ICHOM framework.[12, 48, 64] Four studies used the COSMIN/COMET guideline[39, 40, 234 
76, 84] and a fifth study[37] used the COSMIN standrds for the selection of health status 235 
measurement instruments.[86] Eleven studies[11, 17, 32, 36, 87-93] referred to other 236 
guidance, for example guidelines from ECCO GuiCom; guidance by Physical Rehabilitation 237 
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Outcomes Measures, published by the Canadian Physiot erapy Association; previous work 238 
by Hudak et al[94] or Dworkin et al;[95] other conse us guidelines;[96-101] the HOME 239 
roadmap;[102] the framework for the selection of clini al trial indices proposed by Tugwell 240 
and Bombardier;[103] and guidance from a qualitative e aluation of measures for 241 
psychosocial intervention in dementia care. No guidance was used in 43/118 studies (37%), 242 
whereas in 40/118 studies (34%) it remains unclear whether any form of guidance was used.  243 
 244 
3.1.6. Recommendations for additional research on istruments 245 
In 55/118 studies (47%) recommendations were made for additional validation studies 246 
(n=31), or development of new instruments (n=24).  247 
 248 
3.2. Differences between studies published before and after the publication of the 249 
COSMIN/ COMET guideline 250 
Of the 118 studies included in this review, 92 studies (78%) were published prior to the 251 
publication of the COSMIN/COMET guideline and 26 studies (22%) were published 252 
following its publication. Table 2 provides a comparison of the methods used in studies 253 
published before and after the publication of the COSMIN/COMET guideline. Studies 254 
published following the publication of the COSMIN/COMET guideline were more likely to 255 
base their recommendations on the quality of the outcome measurement instruments, with 256 
8/26 studies (31%) considering the evaluation of the measurement properties of the 257 
instruments and a further 4/26 studies (15%) considering both the quality of the measurement 258 
properties of the outcome measurement instruments and the quality of studies on 259 
measurement properties. Additionally, these studies w re also more likely to comply with the 260 
COSMIN/COMET recommendations on the selection of outc me measurement instruments, 261 
with 11/26 studies (42%) recommending one single instrument for each core outcome 262 
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included in the COS, for which a recommendation could be made, and a further 6/26 studies 263 
(23%) recommending one instrument for all included core outcomes except one. The 264 
inclusion of stakeholders across all groups increased in the post-guideline studies, with the 265 
biggest increase being the inclusion of patients and/or public representatives, which increased 266 
from 20% to 58%. There was also a 31% decrease in the umber of studies that did not 267 
provide any details about stakeholder involvement. Regarding the use of guidance, 12/26 268 
studies (46%) published following the COSMIN/COMET guideline used available guidance 269 
for instrument selection, with 5/26 studies (19%) specifically using the COSMIN/COMET 270 
guideline or other COSMIN guidance.  271 
 272 
Table 2. Methods used in studies published before and after the publication of the 273 








Finding existing outcome measurement instruments 
Used 3 or more sources to find existing outcome measurement 
instruments 
16/92 (17) 5/26 (19) 
Used 2 sources to find existing outcome measurement instruments 30/92 (33) 6/26 (23) 
Used 1 source to find existing outcome measurement instruments 46/92 (50) 15/26 (58) 
Quality assessment of outcome measurement instruments 
(a) Measurement properties 
Considered both the quality of the measurement properties of the outcome 
measurement instruments and the quality of studies on measurement 
properties 
2/92 (2) 4/26 (15) 
Considered the evaluation of the measurement properties of the included 
outcome measurement instruments 
15/92 (16) 8/26 (31) 
Referred to quality criteria but no formal assessment 52/92 (57) 6/26 (23) 
Quality of outcome measurement instruments not taken into account 23/92 (25) 8/26 (31) 
(b) Feasibility 
Feasibility aspects taken into consideration 59/92 (64) 15/26 (58) 
Recommendations on the selection of outcome measurement instruments 
One single instrument for each core outcome 3/92 (2) 8/26 (31) 
One single instrument for each core outcome where a recommendation 
could be made 
9/92 (10) 3/26 (12) 
One instrument for all included core outcomes except one 6/92 (7) 6/26 (23) 
Multiple instruments for all core outcomes 7/92 (8) 0/26 (0) 
Combination of recommendations for each core outcome 67/92 (73) 9/26 (35) 
Consensus procedure used to reach agreement 
Used consensus procedure to get final agreement on the selected 
instruments  
62/92 (67) 18/26 (69) 
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Specified details of the consensus procedure 35/62 ( ) 15/18 (83) 
Stakeholders involved in the selection of outcome measurement instruments 
Clinical experts 50/92 (54) 23/26(88) 
Patients and/or public representatives  18/92 (20) 15/26 (58) 
Non-clinical researchers 26/92 (28) 13/26 (50) 
Regulatory authorities 15/92 (16) 5/26 (19) 
Industry representatives 13/92 (14) 4/26 (15) 
No details provided about the stakeholders involved in selecting the 
outcome measurement instruments 
40/92 (43) 3/26 (12) 
Guidance on instrument selection 
Used published guidance  23/92 (25) 12/26 (46) 
Recommendations for additional research on instruments 
Made recommendations for the development of new instruments or 
additional validation studies 
42/92 (46) 13/26 (50) 
 276 
 277 
4. Discussion  278 
We identified 118 COS development studies that provided recommendations for how to 279 
measure the outcomes included in a COS. Reviewing these studies has enabled us to gain 280 
insight into the methods used by COS developers to select outcome measurement 281 
instruments. Following the publication of the COSMIN/COMET guideline, there has been an 282 
improvement in the methods used, specifically in relation to quality assessment, 283 
recommendations on the selection of instruments, stakeholder involvement, and the use of 284 
published guidance. 285 
 286 
4.1. Finding all existing instruments 287 
COS developers should make better use of the literature to inform their instrument selection 288 
process. Relying solely on expert opinion to find existing outcome measurement instruments, 289 
as 33% of studies did in the current review, may result in only the most commonly used 290 
instruments, or those that are favored by clinicians, being considered. To assist developers in 291 
identifying instruments, COSMIN maintains a database of systematic reviews of outcome 292 
measurement instruments.[104] The ‘COSMIN guideline for systematic reviews of patient-293 
reported outcome measures’[105] can be used for performing a comprehensive literature 294 
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search or full systematic review to find all available instruments if a good quality systematic 295 
review is not available.  296 
 297 
4.2. Quality assessment of instruments 298 
COS developers should take both the quality of the s udies on measurement properties and 299 
the results of the measurement properties of the outcome measurement instruments into 300 
account in their recommendations. This will ensure that the most reliable and valid outcome 301 
measurement instruments are selected. However, only te  of the COS development studies 302 
included in this review considered both aspects. To assist in the assessment of the quality of 303 
the studies, COSMIN has developed a Risk of Bias checklist for use in systematic reviews of 304 
PROMs to assess the risk of bias of studies on measur ment properties.[106] COSMIN has 305 
also proposed quality criteria for measurement properties of health status questionnaires to 306 
assist COS developers in assessing the quality of identified instruments.[106] 307 
 308 
In contrast to the assessment of measurement properties, the feasibility of the identified 309 
instruments was generally taken into consideration in the selection of outcome measurement 310 
instruments. We expect that the number of studies con idering these feasibility aspects will 311 
continue to remain high, following the publication f the COSMIN/COMET guideline in 312 
2016.[2] 313 
 314 
4.3. Generic recommendations on the selection of outcome measurement instruments  315 
COS developers should try to recommend only a single instrument for each individual 316 
outcome included in a COS, to contribute to the overarching goal of uniformity in outcome 317 
reporting and enhance the comparability of clinical tri ls. Exceptions can however be made 318 
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for subpopulations, such as children and adults, were different instruments may be necessary 319 
for the different age groups.  320 
 321 
COS stakeholder groups should include more representative stakeholders, including patients, 322 
when agreeing on the most appropriate outcome measurement instruments. Most COS 323 
stakeholder groups were comprised of clinical experts, while public representatives were 324 
involved in less than one third of studies. This is concerning, as it suggests that the outcome 325 
measures recommended may not be those that public representatives deem to be most 326 
appropriate. Patients are increasingly being included in selecting the outcomes for inclusion 327 
in COS, with 92% of ongoing COS development studies in the COMET database planning to 328 
include some degree of patient input.[107] However, patients and/or public representatives 329 
were only included in the selection of outcome measurement instruments in 28% of COS 330 
studies.  331 
 332 
It could be argued that it is more difficult to include patients in the selection of outcome 333 
measurement instruments than in the selection of the outcomes, because the selection of 334 
instruments is mostly based on studies on measurement properties, which may be difficult for 335 
patients to understand. COS developers may need to a dress additional issues when the 336 
population concerned includes people with cognitive impairment, communication difficulties 337 
or other vulnerabilities, which make participation in such processes challenging. Despite the 338 
complexities involved in the selection of outcome masurement instruments, there has been 339 
an increase in the inclusion of patients and/or public representatives since the publication of 340 
the COSMIN/COMET guideline. Thus, it is certainly possible to involve patients and/or 341 
public representative, including those from vulnerable groups, in this process. However, it 342 
should be acknowledged that these groups are likely to need additional support to participate 343 
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and so in some instances a multi-stage approach, which allows for adequate support, might be 344 
necessary to ensure that engagement is meaningful. One potential means of involvement is 345 
for patients to judge the face and content validity (relevance, comprehensiveness and 346 
comprehensibility) of the available outcome measurement instruments, which are considered 347 
the most important measurement properties.[106, 108] However, it should be noted that this 348 
may not be necessary, if previous published studies have assessed the validity of outcome 349 
measurement instruments with the population in question.  350 
 351 
4.4. Implications 352 
This review has highlighted that the methods used to select the core outcome measurement 353 
instruments vary across studies, with many studies not meeting the recommended standards. 354 
However, the majority of included studies were published prior to the development of the 355 
COSMIN/COMET guideline, in 2016, and so developers may have been unaware of 356 
methodology for selecting outcome measurement instruments. There have however been 357 
clear improvements in the methods used to select out ome measurement instruments in 358 
studies published since the publication of the COSMIN/COMET guideline. It is unclear 359 
whether such improvements are a direct result of the publication of the COSMIN/COMET 360 
guideline or whether other variables are responsible for the pre- and post-guideline reporting 361 
differences. Other potential variables may include increased COS awareness prompting COS 362 
developers to be more thorough in the outcome measur ment instrument selection process. In 363 
addition, the differences in the rate of inclusion of patients may be attributable to increased 364 
public input in health research in general.  365 
 366 
Going forward we hope that COS developers will utilise the COSMIN/COMET guideline, 367 
along with the other resources listed above, to ensur  that recommendations for outcome 368 
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measurement instruments are developed using rigorous methodology. A recent paper by Ju 369 
and colleagues[109] highlights how to apply the COSMIN/COMET guidance when 370 
identifying outcome measurement instruments.  371 
 372 
Apart from the COSMIN/COMET guideline, other guidelin s can also be used to guide the 373 
selection of outcome measurement instruments for COS, for example the OMERACT 374 
Handbook[110] or HOME roadmap.[102] Different guidel n s put different emphasis on 375 
different steps of the process. For example, in contrast to the COSMIN/COMET guideline 376 
and HOME roadmap, the OMERACT process does not require a search to find ALL 377 
available instruments but starts with a selection of i struments that seem to have good match 378 
with the target domain and are considered feasible. Both the COSMIN/COMET guideline 379 
and the OMERACT Handbook address the need for good c ntent validity of outcome 380 
measurement instruments. Therefore, we suggest that, w en resources are limited, COS 381 
developers should evaluate the content validity of available instruments, if this has not been 382 
done previously, with a small number of patients in their stakeholder group, e.g. ask patients 383 
to evaluate the relevance, comprehensiveness and comprehensibility of all items/tests. The 384 
COSMIN methodology for assessing content validity of PROMs can be used for further 385 
guidance.[108] Nevertheless, it should be acknowledged that while guidelines are important, 386 
some flexibility should be employed to best facilitate the participation of patients and/or 387 
public representatives.  388 
 389 
4.5. Limitations 390 
All of the studies included in the current review were identified from the annual COMET 391 
systematic review of COS. We did not perform a systematic search for all studies relating to 392 
how outcomes should be measured. For example, COS groups may perform systematic 393 
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reviews of outcome measurement instruments and select th ir instruments based on these 394 
reviews, but may not publish a separate paper on the selection process for the outcome 395 
measurement instruments; therefore, we cannot be certain that we have identified all relevant 396 
studies. However, we did check the references of all included papers and authors of COS 397 
studies were contacted to provide additional information. 398 
 399 
4.6. Conclusions 400 
In conclusion, COS developers need to make better use of the guidance available when 401 
agreeing on how to measure the outcomes included in COS. Specifically, developers need to 402 
ensure that outcome measurement instruments are of sufficient quality and especially have 403 
sufficient content validity. Furthermore, developers should aim to adhere to uniformity by 404 
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Appendix A. Search strategy  
Search terms for MEDLINE  
 Randomised trial and systematic review terms 
1 Health Services/ut [Utilization] 
2 registries/ 
3 systematic review.mp. 
4 structured review.ti. 
5 evidence based medicine.ab. 
6 exp Clinical Trials as Topic/ 
7 clinical trial$.ab. 
8 randomised controlled trial$.ti,ab. 
9 randomised trial$.ti,ab. 
10 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 
 Methodology terms 
11 workgroup$.mp. 
12 standard$ outcome$.mp. 
13 Practice Guideline/ 
14 clinical database.mp. 
15 patient important outcome$.mp. 
16 (standard$ adj3 reporting).mp. 
17 congresses.pt. 
18 Delphi Technique/ 
19 (recommend$ adj3 outcome$).mp. 
20 consensus development conference.pt. 
21 outcome$ reporting.mp. 
22 priorit$ symptom$.mp. 
23 (task force adj3 outcome$).mp. 
24 appropriate outcome$.mp. 
25 research design/ 
26 endpoint determination/ 
27 consensus development conference/ 
28 patient participation/ 
29 consensus.mp. 
30 workshop.mp. 
31 Consensus Development Conferences, NIH as Topic/ 




11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 
or 27 or 28 or 29 or 30 or 31 or 32 
 Outcome terms 
34 outcome$.mp. 
35 end point$.mp. 
36 (core adj3 set).mp. 
37 treatment emergent problem$.mp. 
38 exp outcome Assessment Health Care/ 
39 Treatment Outcome/ 
40 Quality of Life/ 
41 34 or 35 or 36 or 37 or 38 or 39 or 40 
 Key terms targeted  
42 clinical-study design.mp. 
43 patient$ perspective$.ti. 
44 outcome$.mp. and delphi.ti. 
45 (outcome$ and delphi).ab. 
46 (perspective$ adj3 outcome$).ti. 
47 core outcome$.ti,ab. 
48 core set$.ti,ab. 
49 clinical trial design$.ti. 
50 design$ clinical trial$.ti. 
51 (consensus and outcome$).ti. 
52 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 
53 10 and 33 and 41 
54 52 or 53 
 
Search terms for SCOPUS  
((((INDEXTERMS(registries)) OR (INDEXTERMS(clinical trials as topic)) OR 
(ABS("evidence based medicine")) OR (ABS("clinical trial*")) OR (INDEXTERMS("Health 
Services Utilization")) OR (TITLE-ABS-KEY("SYSTEMATIC REVIEW")) OR 
(TITLE("structured review"))) OR (TITLE OR ABS("randomised controlled trial*")) OR 
(TITLE OR ABS (randomised trial*))) AND (((TITLE-ABS-KEY(workgroup*)) OR (TITLE-
ABS-KEY(standard* outcome*)) OR (INDEXTERMS(practice guideline)) OR (TITLE-ABS-
KEY("clinical database")) OR (TITLE-ABS-KEY("patient important outcome*")) OR 
(TITLE-ABS-KEY("standard* outcome*")) OR (INDEXTERMS(delphi technique))) OR 
((TITLE-ABS-KEY(recommend* W/3 outcome*)) OR (TITLE-ABS-KEY(standard* W/3 
reporting*)) OR (TITLE-ABS-KEY(task force W/3 outcome*)) OR (TITLE-ABS-
KEY("appropriate outcome*")) OR (TITLE-ABS-KEY("outcome* reporting")) OR (TITLE-
ABS-KEY("priorit* symptom*")) OR (INDEXTERMS(focus group)) 
(INDEXTERMS(research design))) OR ((INDEXTERMS(endpoint determination)) OR 
(INDEXTERMS(consensus development conference)) OR (INDEXTERMS(patient 
participation)) OR (TITLE-ABS-KEY(consensus)) OR (TITLE-ABS-KEY(workshop)))) 
AND 74) OR (((TITLE("design* clinical trials")) OR (TITLE(consensus AND outcome*)) OR 
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(TITLE-ABS-KEY("clinical-study design")) OR (TITLE("patient* perspective*")) OR 
(ABS(outcome* AND delphi)) OR (TITLE(outcome* AND delphi)) OR (TITLE(perspective* 
W/3 outcome*)) OR (ABS("core outcome*") OR TITLE("core outcome*"))) OR ((ABS("core 
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Appendix C. Details of data extraction   
Data extraction item Details 
Reference 
Reference no. Consecutive number 
Full reference Full bibliographic information 
Reference First author; year 
Extractor Initials 
Abstract Full abstract 
Study characteristics 
Geographical location (country) 
(locations of authors/ steering committee) 
Free text 
Geographical location (country) 
(locations of participants)   
Free text 
Language Free text 
Construct(s) Free text 
Disease area (COMET classification) Free text 
Target population Free text 
Age group o Infants/children, adolescents 
o Adults 
o Not specified 
Number of outcomes (what) for which an instrument (how) could be 
recommended 
o Free text 
Type of study o What and how together 
o In two separate stages 
Comments o Free text 
Methods for measurement selection 
Methods used to select core outcome measurement instruments  o finding existing instruments 
 
 35
o quality assessment of instruments 
o recommendations on the selection of instruments 
o other, specify 
Steps taken in finding existing instruments  o performing a systematic review, including search in MEDLINE (and 
EMBASE) 
o use existing review(s) 
o reference lists 
o expert opinion 
o other sources, specify 
Quality assessment of the instruments  o evaluation quality of the study (i.e. COSMIN, EMPRO) 
o evaluation quality of the measurement properties (i. . quality criteria 
applied) 
o other, specify 
o not done 
Quality of evidence taken into consideration  o yes, specify 
o no 
o unclear, no information given 
Feasibility aspects taken into consideration  o yes, specify 
o no 
o unclear, no information given 
Arguments used for selecting instruments if no strict quality criteria were 
used 
o Free text 
Recommendations on the selection of instruments  o one instrument 
o multiple instruments for different subgroups 
o multiple instruments 
o other, specify 
o no instrument recommended 
o not reported 
Consensus procedure used to agree on the instrument(s) included in the 
COS  




o other, specify 
COSMIN/COMET guideline used in selecting instruments? o yes 
o no 
Any guidance (i.e. published guidance) used in selecting instruments? o yes, specify 
o no 
o unclear, no information given 
Were the methods used for finding PROMs different vs. finding non-
PROMs? 
o yes, specify the methods used 
o no 
o not applicable 
Recommendations for research on validation studies, new or additional 
instruments made? 
o Yes, specify 
o no 
Stakeholder groups involved in selecting instruments o clinical experts 
o public representatives (including patients) 
o non-clinical research experts 
o authorities 
o industry representatives 
o others, specify 
o no details given 





Appendix D. Details on COS development studies (n=118) 
Reference  
(1st author, year) 
Geographical location 
(authors/ steering committee)  
Geographical location 
(participants)  


















Type of study 
(1= what and 
how together, 
2= in two 
separate stages) 
Bombardier 2000 Canada Canada Orthopaedics & 
trauma 
Spinal disorders 3 5 1 
Khanna 2008 USA, Italy, UK USA, Canada, South America, Asia, and 
Europe 
Rheumatology Systemic sclerosis (scleroderma) 3 11 2 
Clements 2012 USA, France USA, France Rheumatology Muskuloskeletal pain and 
systemic sclerosis (scleroderma) 
2 9 1 
Merkel 2009 USA, Germany, France, UK, the 
Netherlands, Turkey 
USA, Germany, France, UK, the 
Netherlands, Turkey, and likely additional 
countries not listed 
Rheumatology Small-vessel vasculitis (ANCA-
associated vasculitis) 
3 3 2 
Hellmich 2007 5 EU countries, USA (not further 
specified) 
Germany, UK, the Netherlands, France, 
USA, Turkey 
Rheumatology Small-vessel vasculitis (ANCA-
associated vasculitis) 
1, 2 7 1 
Douglas 2009 USA, Europe, Canada USA, UK, Canada, Australia, Austria, Israel, 
Ireland, Spain, Denmark, Turkey, Korea, the 
Netherlands, Belgium, Iran 
Endocrine & 
metabolic 
Thyroid eye disease  3 14 1 
Langguth 2007 Germany, New Zealand, Brazil, 
Sweden, USA, Italy, Belgium, 
Spain, France, the Netherlands, 
Colombia 
Germany, New Zealand, Brazil, Sweden, 
USA, Italy, Belgium, Spain, France, the 
Netherlands, Colombia 
Ear, nose & throat Tinnitus 3 4 1 
Clifton 1992 USA USA, UK, the Netherlands Neurology Traumatic brain injury  2 8 1 
Wood 1995 UK, USA, France, Canada, Belgium UK, USA, France, Canada, Belgium Infectious diseases Herpes zoster 3 8 1 
Hoeper 2004 Germany, USA, UK, Poland not reported Heart & circulation Pulmonary arterial hypertension 3 6 1 
Distler 2008 Switzerland, Germany, UK, France, 
Italy, Australia, USA 
North America, Europe, Asia, Australia  Heart & circulation Pulmonary arterial hypertension 
related Systemic Sclerosis 
3 7 1 
Penzien 2005 USA USA, unknown Neurology Recurrent migraine and tension-
type headache  
1, 2 11 1 
Becker 2011 USA USA, France, Austria, Canada, Australia,  Heart & circulation Cardiac arrest 3 5 1 
Felson 1993 USA, the Netherlands, Canada not reportd Rheumatology Rheumatoid arthritis 3 7 2 
Abellan van Kan 
2011 
France, USA USA, France, uknown  Healthcare of older 
people 





Gladman 2007 Canada, USA, UK, Australia, New 
Zealand, Italy, the Netherlands, 
Argentina, Ireland, Germany, Brazil 
Canada, USA, UK, Australia, New Zealand, 
Italy, the Netherlands, Argentina, Ireland, 
Germany, Brazil, unknown 
Rheumatology Psoriatic arthritis 3 6 2 
Dorman 2009 UK, USA, Australia UK, USA, Australia Health care of older 
people 
Dyspnea or breathlessness in 
palliative care 
3 8 1 
Levine 2003 USA USA Urology Peyronie's disease 3 5 1 
Barlow 2003 UK UK Infectious diseases Community-acquired diseases 3 5 1 
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Higashida 2003 USA USA Heart & circulation Acute ischemic stroke 2 15 1 
Miller 2001 US, UK, Hungary, Sweden, Czech 
Republic 
USA, Hungary, Czech Republic, Sweden, 
UK, Israel, Mexico, France, Germany, the 
Netherlands, Canada, Guatemala, Italy, 
Korea 
Rheumatology Idiopathic inflammatory 
myopathies (IIM) 
1,2 7 1 
Canonica 2007 Italy, Argentina, France, US, 
Denmark, South Africa, Finland 
Italy, Argentina, France, US, Denmark, 
South Africa, Finland 
Lungs & airways Respiratory allergy 3 7 1 
Vellas 2008 France, Portugal, UK France, Portugal, UK, Belgium, Denmark, 
the Netherlands, Switzerland, Italy, 
Germany, Sweden, USA 





Miller 1999 USA, UK USA, UK, Canada, France, Sweden, the 
Netherlands, Swtizerland, Japan, Italy; 1998 
conference uknown 
Neurology  Amyotrophic lateral 
sclerosis/motor neurone disease  
2 5 1 
Leigh 2004 UK, Japan, Germany, France, USA, 
the Netherlands 
UK, Japan, Germany, France, USA, the 
Netherlands, Switzerland  
Neurology  Amyotrophic lateral 
sclerosis/motor neurone disease  
3 3 1 
Smith 1996 Australia Australia, UK, USA Lungs & airways Asthma 1, 2 4 1 
Reddel 2009 Australia, South Africa, USA, 
France, the Netherlands, UK, 
Canada, New Zealand  
Australia, South Africa, USA, France, the 
Netherlands, UK, Canada, New zealand  
Lungs & airways Asthma 1, 2  7 1 
Busse 2012 USA USA Lungs & airways Asthma 1, 2 6 (age 5-11) 
6 (age 12+) 
 
1 
Micke 2002 Germany Germany Other Benign/ non-malignnt disease 3 5 1 
Carlson 2003 USA, Canada USA Mental health Bipolar disorder 1  8 1 
Chow 2002 Canada, UK, USA Canada, USA, UK, the Netherlands  Cancer Bone metastases 3 8 1 
Partsch 2010 Austria, USA, Spain, Belgium, UK, 
Poland, Serbia, Hungary, Sweden, 
Germany, France, Australia 
Austria, USA, Spain, Belgium, UK, Poland, 
Serbia, Hungary, Sweden, Germany, France, 
Australia, Italy, the Netherlands, Norway, 
Switzerland 
Cancer Breast cancer related 
lymphedema (BCRL) 
3 18 1 
Pallis 2011 Greece, UK, Belgium, Germany, 
the Netherlands, France, Italy, 
Switzerland  
Greece, Belgium, UK, Germany, Italy, 
France, the Netherlands, Switzerland, 
Cyprus, Austria  
Cancer Solid tumors 2 6 1 
Pavletic 2006 USA, Austria, Canada USA, Austria, Canada Blood disorders Chronic graft-versus-host disease 
(GVHD) 
1, 2 3 1 
Vargus-Adams, 
2009 
USA USA Neurology; Child 
health 
Cerebral palsy 1 8 2 
Van Brussel, 2011 the Netherlands the Netherlands  Child health Children (and adolescents) with 
juvenile idiopathic arthritis, 
osteogenesis imperfecta, 
achondroplasia, hemophilia, 
cerebral palsy, spina bifida, cystic 
fibrosis, and childhood cancer 
1 5 1 
McGrath, 2008 Canada, USA, UK, Sweden Canada, USA, K, Sweden Child health Acute pain or chronic/recurrent 
pain 






Griffiths, 2005 Canada, USA, UK not reported Gastroenterology Crohn's disease 1 4 1 
Ramsey, 1994 USA USA Lungs & airways Cystic fibrosis 1, 2 8 (age <6 years) 




UK, the Netherlands, Italy, Ireland France, Italy, the Netherlands, Ireland, 
Spain, Germany, Belgium, UK, Switzerland, 
Greece, Finland, Sweden, Poland 
Neurology Dementia 3 9 1 
Capri, 1994 Italy, France, UK, Germany, USA, 
Spain 
Italy, France, UK, Germany, USA, Spain Lungs & airways Chronic bronchitis and chronic 
obstructive pulmonary disease 






of natural history 
of disease) 
1 
Meuleman, 2012 Belgium Belgium Gynaecology (deep infiltrative) endometriosis 3 6 1 
Schellinger, 2012 Germany, UK, USA, France  not repo ted  Heart & circulation Acute stroke 3 5 1 
Stout, 2012 USA, Austria, Hungary, Spain, 
Italy, UK, Belgium, the 
Netherlands, Australia, France, 
Germany 
not reported Skin; Heart & 
circulation 
Lower extremity chronic edema 




Reneman, 2013 the Netherlands, Switzerland, USA not reported Orthopaedics & 
trauma 
Chronic and subacute 
musculoskeletal pain 
3 18 1 
Donovan, 2012 USA   USA Tobacco, drugs, & 
alcohol dependence 
Drug dependence treatment  3 2 1 
Vincent, 2010 UK, USA UK, USA, Italy Gynaecology Endometriosis-related pain 3 8 1 
Lamb, 2005 UK, Germany Australia, Europe, North America Orthopaedics & 
trauma 
Community dwelling populations 
(prevention of injury associated 
with falls) 




UK not reported Mental health Forensic mental healt 1, 2 21 2 




Postnatal transmission of HIV 
through breast milk 
1 5 1 
Tonetti, 2012 Italy, UK not reported Dentistry & oral 
health 
Implant dentistry 3 8 2 
Lux, 2004 UK UK, Italy, USA, Argentina, Canada, Japan, 
Oman, Singapore, China, Philippines, 




Infantile spasms and West 
Syndrome (Epilepsy) 
1 9 2 
Mindell, 2006 USA USA Neurology Insomnia 1, 2 4 2 
Giannini, 1997 USA, Italy Sweden, Hungary, USA, Spain, Canada, 
Italy, the Netherlands, Portugal, Germany, 
France, Finland, Russia, Belgium, UK  
Rheumatology Juvenile arthritis 1 6 2 
Ruperto, 2003 Italy, Australia, USA, Sweden, 
Canada, Argentina, the Netherlands, 
Brazil, France, Greece, UK 
Italy, Australia, USA, Sweden, Canada, 
Argentina, the Netherlands, Brazil, France, 
Greece, UK, South Korea, Hungary, Mexico, 
Spain, Czech Republic, Croatia, Israel, 
Switzerland, Finland, Austria, Germany, 
Rheumatology Juvenile systemic lupus 
erythematosus and juvenile 
dermatomyositis 
1 7 (JSLE: 4 disease 
activity; 3 disease 
damage) 
11 (JDM: 6 




Belgium, Norway, Portugal, Bulgaria, 
Denmark, Russia, Turkey, Georgia, Poland, 
Latvia, Yugoslavia, Slovakia  
disease damage) 
Deyo, 1998 USA, Canada, the Netherlands, UK, 
Finland 
USA, Canada, the Netherlands, UK, Finland Orthopaedics & 
trauma 
Low back pain 3 5  1 
Porst, 2010 Germany, Israel, Turkey, USA, 
Korea, Brazil, UK 
Germany, Israel, Turkey, USA, Korea, 
Brazil, UK 
Urology Male sexual dysfunctions 
(erectile disfunction, premature 
ejaculation,  delayed/absent 
ejaculation, libido disorders/loss 
of desire, hypogonadism and 
Peyronie's disease) 
3 2 (clinical trials in 
ED) 
5 (ED PROs) 
3 (clinical trials 
with a gene 
transfer in ED) 
2 (clinical trials in 
PE) 
2 (clinical trials in 
hypogonadism) 
1 
Sanyal, 2011 USA, France not reported Endocrine & 
metabolic 














Bellm, 2002 USA, Canada  not reported Dentistry & oral 
health; Cancer 
Oral mucositis 3 6 2 
Heiligenhaus, 
2012 
Germany, UK, USA, Switzerland, 
France, the Netherlands, Spain, 
Finland, Denmark 
not reported Rheumatology Juvenile idiopathic arthritis 
(JIA)–associated uveitis 
1 11 2 
Hausenloy 2013 UK, Denmark, Italy, Hungary, 
Spain, Germany, South Africa, the 
Netherlands, USA, France 
N/A Heart & circulation At risk of acute myocardial 
ischaemia-reperfusion injury  
3 7 (STEMI 
patients) 
6 (CABG patients) 
1 
Keim 2004 USA, Canada not reported Lungs & airways Respiratory distress in the out-of-
hospital setting 
1, 2 2 2 
Tfelt-Hansen 
2012 
Denmark, Spain, USA, Sweden, 
Italy, Germany, France 
Denmark, Spain, USA, Sweden, Italy, 
Germany, France 
Neurology Acute migraine attacks and 
migraine porphylaxis 
1, 2  11 (acture 
migraine) 
1 
Lipton 1995 USA not reported Neurology Cluster headache 2 6 (migraine 
prophylaxis) 
1 
Bendtsen 2009 Denmark (and likely others, but no 
details for affiliations of co-authors 
given) 
not reported Neurology Tension-type headache 2 1 (children) 1 
Vocci 1999 USA USA (possible others) Tobacco, drugs & 
alcohol dependence 
Smoking cessation, alcohol abuse 
and dependence, cocaine abuse 
1 , 2 (assumed) 5 (acute treatment) 1 
van Riel 1992 the Netherlands N/A Rheumatology Rheumatoid arthritis 3 7 2 
Labs 1999 USA, UK, Switzerland, Germany Switzerland, UK, Sweden, USA, Italy, 
Germany, Canada, Belgium, Greece, Ireland, 
Austria, France 
Heart & circulation Peripheral arterial occlusive 
disease  
3 6 (intermittent 
claudication) 





Merkies 2006 the Netherlands France, Italy, the Netherlands, UK, USA Neurology Peripheral neuropathy 3 4 (painful 
neuropathy) 






Reilly 2006 UK, Belgium, Italy Austria, Belgium, Can da, Czech Republic, 
France, Germany, Italy, the Netherlands, 
Spain, UK, USA 
Neurology Charcot-marie-tooth disease type 
1 A  
2 4 1 
Leon 2011 the Netherlands, USA, France, 
Canada, Switzerland 
the Netherlands, USA, Germany, Canada, 
Switzerland, France, UK 
Heart & circulation Transcatheter aortic valve 
implantation  
3 16 1 
Wilde 2010 USA, Germany US, Germany  Neurology Traum tic brain injury  2 8 1 
Chen 2014 USA, Canada not reported Cancer Localized and advanced prostate 
cancer 





Diehm 2013 Switzerland, Belgium, the 
Netherlands 
Switzerland, Belgium, the Netherlands, USA 
(potentially other European countries as 
well) 
Heart & circulation Aortic dissection 2 21 1 
Feldman 2015 Canada Canada Rehabilitation Enhanced re overy after surgery 
pathways following major 
abdominal surgery 
3 5 (intermediate 
recovery phase: in 
hospital) 




Goldhahn 2014 Switzerland, Canada, USA Switzerland, Canada, UK, Belgium, USA, 
the Netherlands, Italy, France, Ireland 
Orthopaedics & 
trauma 
Distal radius fractures 2 5 1 
Haywood 2014 UK UK Orthopaedics & 
trauma 
Hip fracture  2 5 1 
Kloppenburg 
2015 
the Netherlands, Norway, UK, 
Canada 
not reported Rheumatology Hand osteoarthritis 3 6 (all settings) 






Wolters 2013 USA USA, UK Genetic disorders Neurofibromatoses 1, 2 4 1 
Ruemmele 2014 France, USA, Canada, Finland, 
Portugal, Israel, the Netherlands, 
Hungary, Belgium, UK 
France, USA, Canada, Finland, Portugal, 
Israel, the Netherlands, Hungary, Belgium, 
UK 
Gastroneterology Crohn's disease and ulcerative 
colitis 
1 6 1 
Khanna 2015 USA, Canada, Australia, New 
Zealand, UK 
USA, Canada, Australia, New Zealand, UK, 
South Africa, France, Greece, Portugal, 
Germany, Italy, the Netherlands, Spain, 
Brazil, Argentina, Uruguay, Hungary, 
Belgium, Switzerland, Sweden, Bulgaria, 
Norway, Finland, Denmark, Korea, Turkey, 
Poland, Japan, India, Pakistan, Ukraine, 
Mexico, Chile, Ireland 
Lungs & airways Connective tissue diseases-
associated interstitial lung disease  
3 7 1 
Ball 2013 UK UK Orthopaedics & 
trauma 
Dupuytren's disease 2 5 1 
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Paul 2014 UK, Ireland, New Zealand, USA UK, Ireland, New Zealand, USA Neurology Multiple Sclerosis  3 7 1 
van den Bos 2014 the Netherlands, UK, France, USA, 
Belgium, Germany 
UK, Spain, USA, the Netherlands, France, 
Italy, Ireland, Austria, Germany, Belgium, 
Canada 
Cancer Localised prostate cancer 2 (assumed) 4 1 
Van den Bos 2015 the Netherlands, USA, Germany, 
Canada, UK, Switzerland, France 
the Netherlands, USA, Germany, Canada, 
UK, Switzerland, France, Norway, Italy, 
Austria, Japan, Belgium 
Cancer Localised prostate cancer 3 8 1 
Deyo 2014 USA USA Orthopaedics & 
trauma 
Chronic lower back pain 2 (assumed) 6 1 
Pinder 2015 UK UK Orthopaedics & 
trauma 
Scaphoid nonunion fracture  2 4 2 




Hirschsprung's disease in high-
income countries 
1 10 2 
Grieve 2017 UK, the Netherlands, Germany, 
Switzerland, USA, Canada, 
Denmark, Israel 
Switzerland, Germany, the Netherlands, 
Canada, USA, Denmark, Norway, Israel, 
Australia, New Zealand, South Africa, 
Japan, Argentina, Brazil, UK 
Anaesthesia & pain 
control 
Chronic regional pain syndrome 2 7 2 
Hernandez Yenty 
2016 
the Netherlands the Netherlands Other Congenital or cquired inverted 
nipples in females 
2 6 1 
Kenny 2018 UK, Australia, Denmark, Brazil, 
USA, Canada, Sweden, China, 
Japan, Kuwait 
UK, Australia, Denmark, Brazil, USA, 
Canada, Sweden, China, Japan, Kuwait; E-
Delphi completed by dentists in over 30 
countris but does not provide information 
Dentistry & oral 
health 
Traumatic fental injury 1, 2 13 (all injury 
types) 
10 (injury 
specific)   
2 
Klokkerud 2017 Norway Norway Musculoskeletal 
Disease 
MSD undergoing rehabilitation 2 (assumed) 10 2 
Marrie 2016 Canada, Italy, UK, USA  USA, UK, Germany, Canada, France, 
Denmark, Sweden, the Netherlands 
Neurology Relapsing remitting MS or 
primary progressive MS 
3 6 1 
McNamara 2015 USA, Australia, Spain, Sweden, 
Singapore, India, UK 
USA, Australia, Sweden, Singapore, India, 
UK 
Heart & circulation Coronary artery disease 3 13 1 
Nabbout 2018 France, UK France, Italy, USA, Australia, UK Neurology; Child 
health 
Dravet syndrome 1, 2 5 1 
Nikiphorou 2017 UK, the Netherlands UK Rheumatology Rheumatoid arthritis 2 (assumed) 10 1 
Obbarius 2017 Germany, USA, UK, Canada, the 
Netherlands, Saudi Arabia, Japan, 
Sweden, Australia, Uganda, Brazil, 
Chile 
Australia, Brazil, Canada, Chile, Germany, 
India, Japan, the Netherlands, Sweden, 
Uganda, UK, USA 
Mental health Depression and/or anxiety 1, 2 10 1 
Ong 2017 Australia, USA, the Netherlands, 
Ireland, Belgium, Mexico, Sweden, 
Malaysia  
Australia, USA, the Netherlands, Ireland, 
Belgium, Mexico, Sweden, Malaysia  
Cancer pathologically confirmed 
American Joint Committee of 
Cancer (AJCC) patients with 
stages 0 to IVBC 
2 26 1 
Rief 2017 Germany, UK, Denmark, the 
Netherlands, Norway 
not reported Mental health Somatic symptoms and associated 
disorders 
3 11 1 
Ruiz 2017 USA, Italy, Canada, Spain, UK,  not reported Heart & circulation PVL closure devices 3 8 1 
Sharrock 2016 UK N/A Orthopaedics & 
trauma 
Abdominal closure following 
damage control laparotomy for 
trauma 
1, 2 (assumed) 5 2 
Stoner 2016 USA Italy, UK Heart & circulation Peripheral arterial disease 2 (assumed) 5 1 
Needham 2017 USA USA, UK, Australia, Canada, Singapore, 
China, France, Germany, Belgium, Greece, 
Rehabilitation; 
Lungs & airways 
Acute respiratory failure 
survivors 
2 (assumed) 8 2 
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the Netherlands, Norway, Italy, Ireland, 
Crazil, Panama 
Wallace 2019 Australia, Canada, Germany, UK, 
USA, Ireland, Sweden 
Australia, Canada, Germany, UK, USA, 
Ireland, Sweden 
Neurology Post-stroke aphasia 2 5 2 
Warners 2017 the Netherlands, Canada, Belgium, 
USA 
N/A Gastroenterology Eosinophilic esophagitis disease 1, 2  4 2 
Webster 2017 UK, Germany UK Neurology Mild or moderate dementia 2 2 1 
Williams 2018 USA, France, Israel, China USA, France, Israel, China Anaesthesia & pain 
control 
Pediatric sedation procedures 1 4 2 
Dohner 2017 Germany, USA, UK, Italy, France, 
Japan, the Netherlands, Spain, 
Taiwan, Australia 
Germany, USA, UK, Italy, France, Japan, 
the Netherlands, Spain, Taiwan, Australia 
Cancer Acute myeloid leukemia 2 4 1 
Kwakkel 2017 USA, Australia, UK not reported Neurology; 
Rehabilitation 
Sensorimotor recovery after 
stroke 
2 7 1 
Allin 2018 UK UK + other high income countries (not 
reported) 
Gastroenterology Gastroschisis 1 8 2 
Balakrishnan 
2018 
USA, Argentina, Canada, France, 
Switzerland, Ireland, Italy, Chile, 
Australia 
8 countries within North and South America, 
Europe, and Australia (not reported) 






















Haywood 2018 USA, UK, the Netherlands, 
Germany, Finland, Sweden, 
Belgium, Australia, Canada, 
Singapore 
UK, the Netherlands, Finland, Germany, 
Belgium, Sweden, USA, Canada, Singapore, 
Australia, New Zealand + 4 others 
Heart & circulation Cardiac arrest 2 3 2 
Hopkins 2018 UK, Australia, New Zealand, the 
Netherlands, Belgium, Germany, 
USA, Singapore, Canada 
UK, USA Ear, nose & throat Chronic rhinosinusitis   2 15 1 
Iorio 2018 Canada, USA North America, Europe, possbily others 
(countries not reported) 
Blood disorders  Haemophilia 1, 2 (assumed) 6 1 
Pushpanathan 
2018 
UK, USA N/A Anaesthesia & pain 
control 
Postoperative pain  2 6 1 
Radner 2018 Austria, Sweden, UK, France, 
Romania, the Netherlands, 
Germany, Spain, Switzerland, 
Norway, Denmark, USA, Portugal, 
28 different European countries (not 
reported)  




Chiarotto 2018 the Netherlands, USA, Australia, 
Brazil, UK, Norway, Spain 
USA, the Netherlands, Australia, UK, Brazil, 
Italy, Norway, Canada, Spain, Germany, 
Finland, Denmark, Switzerland + others 
Orthopaedics & 
trauma 
non-specific low back pain 2 4 2 
Spuls 2017 Germany 
the Netherlands, UK, Brazil, Israel, 
USA, Japan, France, Australia, 
Sweden 
Germany, the Netherlands, UK, Brazil, 
Israel, USA, Japan, France, Australia, 
Sweden, Canada, Denmark, China, Tanzania 
Skin Eczema 1, 2 4 2 
 
What is new? 
 
Key findings 
• Methods used to select core outcome measurement instruments vary across studies, 
with many studies not meeting the recommended standards. 
• Methods used to select outcome measurement instruments have improved since the 
publication of the COSMIN/COMET guideline. 
 
What this adds to what is known? 
• This is the first study to assess how the outcome measurement instruments 
recommended in existing core outcome sets have been selected and whether good 
practices are being followed. 
 
What is the implication, what should change now? 
• Core outcome set developers need to make better use of the guidance available when 
agreeing on how to measure the outcomes included in core outcome sets.  
• Developers need to ensure that outcome measurement instruments are of sufficient 
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